NeutraKine® IL-17A Monoclonal antibody
NeutraKine® IL-17A Monoclonal Antibody for Neutralization, ELISA
Host / Isotype
Mouse / IgG1
Cat no : 69021-1-Ig
69021-1-Ig targets NeutraKine® IL-17A in Neutralization applications and shows reactivity with Human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||human Humankine IL-17A protein HZ-1113|
|Full Name||interleukin 17A|
|Gene ID (NCBI)||3605|
|Purification Method||Protein G purification|
|Storage Buffer||Sterile PBS.|
|Reconstitution||This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.|
|Stability and Storage||Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.|
IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.
This antibody can be used to neutralize the bioactivity of IL-17A.